Evercore ISI Group Initiates Coverage On Foghorn Therapeutics with Outperform Rating, Announces Price Target of $20
Portfolio Pulse from Benzinga Newsdesk
Evercore ISI Group has initiated coverage on Foghorn Therapeutics with an Outperform rating and set a price target of $20.
August 19, 2024 | 1:56 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Evercore ISI Group has initiated coverage on Foghorn Therapeutics with an Outperform rating and a price target of $20, indicating a positive outlook.
The initiation of coverage with an Outperform rating and a specific price target of $20 by Evercore ISI Group suggests a positive sentiment towards Foghorn Therapeutics. This is likely to boost investor confidence and potentially lead to a short-term increase in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100